Vycellix Announces Formation of Scientific Advisory Board
Tags:
Immuno-Oncology
Advisory Board
SAB Comprised of Key Opinion Leaders Advancing Next-Generation Cell & Gene-based Immuno-Oncology Therapeutic Platforms
TAMPA, Fla. and STOCKHOLM--(BUSINESS WIRE)--Vycellix™, Inc. today announced that the Company, founded by leading medical researchers at Sweden’s world renowned Karolinska Institutet, has appointed the inaugural members of its Scientific Advisory Board (SAB). Vycellix’s SAB is comprised of distinguished research scientists, professors and clinicians recognized as key opinion leaders in the fields of immuno-oncology and gene and cell therapies, collectively representing prestigious academic institutions, cancer centers and private industry.
The appointments to Vycellix’s SAB include:
Vycellix’s CEO, Evren Alici, M.D., Ph.D., stated, “It is a profound privilege for our team to collaborate with such an esteemed group of scientific and medical key opinion leaders who have contributed important advances in the field of gene and cell therapies. Their expertise and multi-disciplinary scientific perspectives should be of the utmost value in supporting advancement of Vycellix’s pipeline.” Dr. Alici’s research constellation at Karolinska Institutet is pioneering next-generation gene and cell therapies.
About Vycellix™, Inc.:
Headquartered on the Fowler Campus of the Moffitt Cancer Center, Tampa, Florida, Vycellix is a closely-held immunotherapy-focused, discovery company with the mission to fundamentally impact the challenges that currently prevail in the area of cell and gene based-therapies. The Company is engaged in the development of proprietary approaches for cell-based cancer immunotherapeutic products and to improve patient outcomes.
Vycellix’s scientific discoveries coupled with a portfolio of small molecule and RNA modulators address current limitations for cell and gene therapies, including the need to accelerate speed of production, lower costs, ensure end-cell viability and persistence, and improve patient outcomes. The Company’s innovative solutions offer the potential to significantly optimize processes for: cell reprogramming; enhancing cell potency; and improving cell expansion. Additionally, the Company is leveraging its assets to develop an early-stage pipeline of multifaceted, next-generation NK cell therapies targeting hematological malignancies and solid tumors, including its ReOpt-NK™ (Retargeted Optimized NK cell) therapy.
The Company’s products were all discovered by scientists at the world renowned Karolinska Institutet (KI) in Stockholm, Sweden. KI is globally recognized for its Nobel Assembly, which awards the Nobel Prize in Physiology or Medicine.
For more information, please visit the Company’s website at: www.Vycellix.com and follow its Twitter feed at: @Vycellix.
Contacts
Vycellix Corporate Contact: Douglas W. Calder, President Phone: (772)-418-6302 Email: dcalder@vycellix.com
Vycellix Corporate Contact: Douglas W. Calder, President Phone: (772)-418-6302 Email: dcalder@vycellix.com
